Abstract

Bordetella (B.) pertussis resurgence affects not only the unvaccinated, but also the vaccinated population. Different vaccines are available, however, it is currently unknown whether the type of childhood vaccination has an influence on antibody responses following a B. pertussis infection later in life. Therefore, the study aim was to profile serum antibody responses in young adults with suspected B. pertussis infections, immunized during childhood with either whole-cell (wPV) or monocomponent acellular pertussis (aPV) vaccines. Serum anti-pertussis toxin (PTx) IgG antibody levels served as an indicator for a recent B. pertussis infection. Leftover sera from a diagnostic laboratory from 36 Danish individuals were included and divided into four groups based on immunization background (aPV vs. wPV) and serum anti-PTx IgG levels (– vs. +). Pertussis-specific IgG/IgA antibody levels and antigen specificity were determined by using multiplex immunoassays (MIA), one- and two-dimensional immunoblotting (1 & 2DEWB), and mass spectrometry. Besides enhanced anti-PTx levels, wPV(+) and aPV(+) groups showed increased IgG and IgA levels against pertactin, filamentous hemagglutinin, fimbriae 2/3, and pertussis outer membrane vesicles (OMV). In the wPV(–) and aPV(–) groups, only low levels of anti-OMV antibodies were detected. 1DEWB demonstrated that antibody patterns differed between groups but also between individuals with the same immunization background and anti-PTx levels. 2DWB analysis for serum IgG revealed 133 immunogenic antigens of which 40 were significantly different between groups allowing to differentiate wPV(+) and aPV(+) groups. Similarly, for serum IgA, 7 of 47 immunogenic protein spots were significantly different. This study demonstrated that B. pertussis infection-induced antibody responses were distinct on antigen level between individuals with either wPV or aPV immunization background. Importantly, only 2DEWB and not MIA could detect these differences indicating the potential of this method. Moreover, in individuals immunized with an aPV containing only PTx in childhood, the infection-induced antibody responses were not limited to PTx alone.

Highlights

  • Pertussis vaccines have been in use since the middle of the twentieth century and have successfully decreased the incidence of pertussis

  • The samples were divided in four groups (n = 9) (Table 1) based on a differentiation in immunization background and serum anti-pertussis toxin (PTx) IgG levels (– vs. +) previously measured with a diagnostic anti-PTx enzyme-linked immunosorbent assays (ELISA) performed at Statens Serum Institut

  • A multiplex immunoassays (MIA) was performed to determine the serum IgG antibody levels directed against PTx, Prn, filamentous hemagglutinin (FHA), and fimbriae type 2 and antigens (Fim2/3)

Read more

Summary

Introduction

Pertussis vaccines have been in use since the middle of the twentieth century and have successfully decreased the incidence of pertussis. Despite worldwide pertussis immunizations, an increase in pertussis cases has been observed both in developing countries that are using inactivated wholecell pertussis vaccines (wPV) as well as in industrialized countries that mainly use acellular pertussis vaccines (aPV) [1]. The observed increases in pertussis are thought to be a combination of improved surveillance, improved diagnostic methods, the emergence of more virulent Bordetella (B.) pertussis strains as well as rapid waning of aPV-induced immunity and the failure of current pertussis vaccines to prevent infection and transmission on the longer term [3, 4]. Antibody responses to pertussis toxoid and pertussis toxin (PTx) are protective [6] and are used to monitor pertussis vaccine- and B. pertussis infection-induced responses [7]. Anti-PTx antibodies alone have been shown to be sufficient to protect against pertussis disease [8, 9]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call